CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
Portfolio Pulse from Benzinga Newsdesk
CureVac has advanced its cancer vaccine candidate CVGBM to Part B of its Phase 1 study in patients with resected glioblastoma. The first patient has been administered the dose-confirmation, and Part B is expected to include up to 20 patients to gather extended data on safety, tolerability, and immunogenicity.
August 15, 2024 | 11:05 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CureVac has moved its cancer vaccine candidate CVGBM to Part B of its Phase 1 study, with the first patient dosed and up to 20 patients to be included. This advancement could positively impact the stock as it shows progress in their clinical trials.
The advancement to Part B of the Phase 1 study indicates progress in CureVac's clinical trials, which is a positive development. This could lead to increased investor confidence and a potential rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100